- Home
- ACRS vs DOUG Comparison
ACRS vs DOUG Comparison
Compare ACRS & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- DOUG
- Stock Information
- Founded
- ACRS 2012
- DOUG 1911
- Country
- ACRS United States
- DOUG United States
- Employees
- ACRS N/A
- DOUG N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- DOUG Building operators
- Sector
- ACRS Health Care
- DOUG Real Estate
- Exchange
- ACRS Nasdaq
- DOUG Nasdaq
- Market Cap
- ACRS 165.7M
- DOUG 161.5M
- IPO Year
- ACRS 2015
- DOUG N/A
- Fundamental
- Price
- ACRS $1.53
- DOUG $2.13
- Analyst Decision
- ACRS Strong Buy
- DOUG
- Analyst Count
- ACRS 9
- DOUG 0
- Target Price
- ACRS $9.25
- DOUG N/A
- AVG Volume (30 Days)
- ACRS 1.4M
- DOUG 620.0K
- Earning Date
- ACRS 08-11-2025
- DOUG 07-31-2025
- Dividend Yield
- ACRS N/A
- DOUG N/A
- EPS Growth
- ACRS N/A
- DOUG N/A
- EPS
- ACRS N/A
- DOUG N/A
- Revenue
- ACRS $17,777,000.00
- DOUG $1,034,406,000.00
- Revenue This Year
- ACRS N/A
- DOUG $17.61
- Revenue Next Year
- ACRS $8.11
- DOUG N/A
- P/E Ratio
- ACRS N/A
- DOUG N/A
- Revenue Growth
- ACRS N/A
- DOUG 8.69
- 52 Week Low
- ACRS $1.05
- DOUG $1.35
- 52 Week High
- ACRS $5.17
- DOUG $3.20
- Technical
- Relative Strength Index (RSI)
- ACRS 47.05
- DOUG 35.87
- Support Level
- ACRS $1.46
- DOUG $2.69
- Resistance Level
- ACRS $1.86
- DOUG $3.03
- Average True Range (ATR)
- ACRS 0.12
- DOUG 0.18
- MACD
- ACRS -0.02
- DOUG -0.03
- Stochastic Oscillator
- ACRS 17.54
- DOUG 9.36
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.